Global Kaposi Sarcoma Market – Industry Trends and Forecast to 2030

Global Kaposi Sarcoma Market, By Type (Epidemic (AIDS Associated) Kaposi Sarcoma, Classic (Mediterranean) Kaposi Sarcoma, Endemic (African) Kaposi Sarcoma, Latrogenic (Transplant-Related) Kaposi Sarcoma), Treatment (HAART, Radiation Therapy, Surgery, Cryosurgery, Chemotherapy, Biological Therapy), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Kaposi Sarcoma Market Analysis and Size

With the increasing prevalence of kaposi sarcoma and the growing number of patients undergoing organ transplantation procedures, patients undergoing organ transplantations are more susceptible to Kaposi sarcoma. Patients having weakened immune systems by acquired immune deficiency syndrome (AIDS) disease or drugs prescribed post-organ transplantation surgery are highly vulnerable to HHV-8. Organ transplant patients are majorly prescribed immunosuppressive agents to avoid their bodies from rejecting the graft, increasing their susceptibility to kaposi sarcoma-associated herpesvirus (KSHV) infection. The increasing use of these agents increases these patients' risk rate by over 100 times more than the general population.

Data Bridge Market Research analyses a growth rate in the kaposi sarcoma market in the forecast period 2023-2020. The expected CAGR of the kaposi sarcoma market tends to be around 4.6% in the mentioned forecast period. The market was valued at USD 140.08 million in 2022 and would grow to USD 200.7 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Kaposi Sarcoma Market Scope and Segmentation

Market Definition

Kaposi sarcoma is a kind of malignant tumor that is majorly associated with skin, mucous membranes, lymph nodes, and other organs. These patches or lesions are usually red or purple. They consist of cancer cells, blood vessels, and blood cells. Human herpesvirus-8 (HHV-8) is chiefly found in the lesion of all patients who are suffering from kaposi sarcoma.

Kaposi Sarcoma Market Dynamics

Drivers

• Increased Rate of Transplantations

According to the records of the Global Observatory on Donation and Transplantation, 1 39,024 organs were transplanted globally in 2017 in total, wherein 90,306 (Kidney), 32,348 (Liver), 7,881 (Heart), 6,084 (Lung), 2,243 (Pancreas), 162 (Small Bowel) transplantations took place. Therefore, these transplantations make the patient more vulnerable to this sarcoma. Thus, it boosts the market growth.

• Growing Strategic Collaborations by Market Players

Lately, several market strategies have been major changes, such as product developments, mergers, and acquisitions. For instance, in 2019, The U.S. FDA granted breakthrough therapy designation to Celgene's pomalidomide (Pomalyst) for the treatment of patients with HIV-positive kaposi sarcoma who have received prior chemotherapy, combined with patients with HIV-negative kaposi sarcoma. This increases the growth of the market.

Opportunities

• Increasing Demand for HAART

Rising demand for antiretroviral therapies leads to patients' faster recovery. For individuals having Epidemic (AIDS-associated) kaposi sarcoma, antiretroviral treatment for HIV or AIDS is generally used before other therapies for the treatment of the tumor and decreasing the symptoms. HAART is preferred as individual therapy or chemotherapy based on the disease's spread and the symptoms of the patients. Therefore, this treatment procedure is greatly boosting the growth of the market.

• Increasing Healthcare Awareness

Health awareness amongst the population is growing, which results in the expectation that drugs boost market growth. The innovative launches in medications for handling squamous cell carcinoma are projected to prompt the market simultaneously. For instance, in September 2014, F. Hoffmann-La Roche Ltd. came up with a new Global Access Program for HIV viral load testing partnered with United Nations Program on HIV/AIDS (UNAIDS), the Clinton Health Access Initiative, the President's Emergency Plan for AIDS Relief, and the Global Fund. The program was completely focused on HIV viral load testing. This creates more opportunities in the market.

Restraints/Challenges

• Shortage In Supply Of Drugs Due To Wide Demand-Supply Gap  

Drug shortage is a public issue affecting low, middle, and high-income countries. Numerous countries have developed several strategies to overcome the problem, while the problem is increasing, affecting the whole world. Different types of drugs, such as essential life-saving drugs, antimicrobial drugs, analgesics, oncology medicines, opioids, radiopharmaceutical, and parenteral products, cardiovascular drugs, are liable to the shortage.

• High Cost

The enormous expenditure on treatment methods hinder the market growth. For instance, according to the data published by Monash University Malaysia in 2016, the prices of major drugs that are used for the treatment of kaposi sarcoma, such as liposomal doxorubicin, liposomal daunorubicin, or paclitaxel along with HAART, are growing significantly, making them unaffordable for middle- and lower-income group patients.

This kaposi sarcoma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the kaposi sarcoma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Kaposi Sarcoma Market Scope

The kaposi sarcoma market is segmented on the basis of type, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Epidemic (AIDS Associated) Kaposi Sarcoma
• Classic (Mediterranean) Kaposi Sarcoma
• Endemic (African) Kaposi Sarcoma
• Latrogenic (Transplant-Related) Kaposi Sarcoma)

Treatment

• HAART
• Radiation Therapy

• Surgery
• Cryosurgery
• Chemotherapy
• Biological Therapy  

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Kaposi Sarcoma Market Regional Analysis/Insights

The kaposi sarcoma market is analyzed and market size insights and trends are provided by type, treatment, distribution channel and end-user as referenced above.

The major countries covered in the kaposi sarcoma market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth because of the increase in the number of Kaposi's sarcoma patients, along with the rise in organ transplants and the intake of immune suppressants.  

Asia-Pacific dominates the market due to the increased prevalence of organ transplantation and such therapies in the region. For instance, as per the Global Observatory On Donation And Transplantation, 1,39,024 organs were transplanted worldwide in 2017, which was quite high thus increasing the market share.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Kaposi Sarcoma Market Share Analysis

The kaposi sarcoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to kaposi sarcoma market.

Key players operating in the kaposi sarcoma market include:

• Johnson & Johnson Private Limited (U.S.)
• Abbott (U.S.)
• AbbVie Inc. (U.S.)
• Bausch Health Companies Inc. (Canada)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Hikma Pharmaceuticals PLC (U.K.)
• Amneal Pharmaceuticals LLC. (U.S.)
• Pfizer Inc (U.S.)
• Mylan N.V. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Bayer AG (Germany)